{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"118.0","value":"1.43"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"12.9","value":"0.71"},{"groupId":"OG002","lowerLimit":"0.1","upperLimit":"10.0","value":"3.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Duration of myeloid growth factor administered starting from Study Day 1 was reported.","dispersionType":"Full Range","groups":[{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. Dose escalation to 9.4 mg/kg was allowed before Protocol Amendment 2.","id":"OG000","title":"Phase 2: Imetelstat Sodium"},{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.","id":"OG001","title":"Phase 3: Imetelstat Sodium"},{"description":"Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.","id":"OG002","title":"Phase 3: Placebo"}],"paramType":"MEDIAN","populationDescription":"Phase 2: All Treated Analysis Set included all participants who received at least one dose of study drug.\n\nPhase 3: ITT Analysis Set included all participants randomized into the Phase 3 study. Overall number of participants analyzed is the number of participants who had at least 1 dose of myeloid growth factors in Phase 2 and Phase 3.","reportingStatus":"POSTED","timeFrame":"Up to 5 years in Phase 2 and up to 3.7 years in Phase 3","title":"Phase 2 and Phase 3: Duration of Myeloid Growth Factors Administration","type":"SECONDARY","unitOfMeasure":"weeks"}